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Objectives: Metformin, the most used oral antidiabetic drug for the treatment of type 2 diabetus mellitus, has proved encouraging 
results when used in the treatment of various types of cancer such as triple-negative breast cancer. Despite compelling evidence 
of a role of metformin as an anticancer drug, the mechanisms by which metformin exerts its oncostatic actions are not fully under-
stood yet. Therefore, we tried to bring new insights by analyzing the anti-neoplastic effect of metformin for hepatocellular carci-
noma-derived stem-like cells treated with conventional combination chemotherapy. Methods: Cancer stem-like cells previusly 
isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination 
of these two protocols. Measurements of lipid peroxidation, reduced glutathione, fluorescein diacetate and proliferation rates were 
determined, apart from the autophagy assay and apoptosis determination by chip flow cytometry. Results: Metformin alone and 
especially metformin in association with PIAF increases oxidative stress within the cells by increasing the levels of lipid peroxids 
as well as decreasing the levels of reduced glutathione. The MTT cell proliferation assay showed decreased prolife ration rates for 
the arm treated with metformin and with the combination of drugs in comparison with the control arm, proving high correlation 
with the oxidative stress results. The autophagy assay and determination of apoptosis by chip flow cytometry confirmed the results 
obtained in the previous assays. Conclusion: Metformin could be used in chemotherapy treatments to induce reactive oxygen species 
and increase the cytostatics effects within the tumor cell. Still, further experiments must be carried out on murine models before 
we can move on and use this drugs in the adjuvant setting for unresectable primary liver cancer.
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In ancient times� �epatology was inexistent� and 
liver was a source of legends and spirituality. Two 
t�ousand years BC t�e liver was t�oug�t to bear t�e 
soul and priests used �epatoscopy in animals as a tool 
for divine connection in order to predict t�e future and 
t�e outcome of a certain military endeavor [�� �]. One 
of t�e most famous legends was written by Hesiod and 
describes Promet�eus stealing fire from Zeus� before 
being puni�sed by t�e king of t�e gods to be c�ained 
to a rock and �aving �is liver eaten by an eagle. But 
t�e liver regenerated and regained its normal size 
overnig�t [�� �]. Over time� t�e progress in t�e field 
of �epatology and liver surgery was mostly for onco-
logic diseases� becoming more and more accurate and 
sop�istiucated and years passed. An important step 
for t�e improved outcome is t�e understanding t�at 
liver cancer must be treated in specialized� interdis-
ciplinary centers w�ere a close relations�ip between 
surgery� internal medicine and basic researc� �ave 
t�e common goal to diagnose and cure t�is infermity.
Liver cancer is t�e 6t� most common cancer world-
wide and t�e t�ird most common cause of cancer 
mortality on t�e planet� wit� more t�an �alf a million 
deat�s annually� indicating t�at t�is pat�ology is not 
only common� but also deadly. T�e �ig�es incidence 
rates are in sub-Sa�aran Africa and eastern Asia� wit� 
C�ina accounting for more t�an 5�% of cases [5]. He-
patocellular carcinoma �HCC� incidence is �ig� among 
young adults and varies among different populations 
and races� suggesting t�at t�is neoplasia is caused 
by seve ral etiologal factors� t�e synergy of w�om �as 
been s�own to be signifficant in �epatocarcinogenesis. 
Risk factors include �epatitis B virus and �epatitis C vi-
rus infection� alco�ol consumption� smoking� aflatoxin 
E exposure� �ormonal intake� occupational exposures 
and c�ronic medical conditions suc� as metabolic 
syndrome� diabetes mellitus� obesity or even t�yroid 
diseases [6]. �ost cases of �epatocellular carcinoma 
are diagnosed in an advanced stage because of t�e 
relatively scarce symptoms. T�e patients survival 
depends not only on tumor c�araceristics� but also 
on t�e extent of t�e undelying disease. Fur�ermore� 
t�e t�erapeutic agents available for HCC and t�e indi-
cations for aggresive t�erapy expand and an increase 
of an interdisciplinary approac� between surgery� ra-
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diot�erapy and c�emot�erapy is expected to c�allenge 
our understanding of prognostic factors for HCC [�].
Encouraging results �ave recently emerged from 
data publis�ed on breast cancer and point towards 
metformin� an oral-antidiabetic used for decades in t�e 
treatment of type � diabetes mellitus� as an efﬁcient 
anticancer drug [8]. �etformin �as already been 
investigated by our team for t�e treatment of WHO 
grade III and IV malignant gliomas in t�e laboratory 
settings [9]� results being conﬁrmed by retrospec-
tive epidemiological studies t�at reported a decrease 
in cancer risk and also a better response to c�emo-
t�erapy of diabetic patients wit� breast cancer treated 
wit� metformin [��].
In t�e current researc� paper� we studied t�e effect 
of metformin plus PIAF �Cisplatin/Interferon α-�b/
Doxorubicin/5-Fluorouracil� wit� Capecitabine repla-
cing 5-Fluorouracil� wit� combination c�emot�erapy 
on malignant liver stem-like cells in order to furt�er 
investigate t�e basic mec�anisms by w�ic� t�is as-
sociation of drugs exerts its action on t�e cancer cell. 
T�e aim of t�e current paper is to investigate t�e cor-
relation between an old drug and t�e best standard-
of-care for unresectable �epatocellular carcinoma� 
wit� t�e final goal of improving t�e t�erapeutic index 
of suc� patients.
MATERIALS AND METHODS
Reactives. �etformin ����-dimet�ylbiguanide 
�ydroc�loride� was purc�esed from Wurwag P�arma 
�Buc�arest� Romania� and used in a final concentra-
tion of �� m� diluted in p�osp�ate buffer solution 
�PBS�. It was added prior to a slig�tly modiffied PIAF 
regimen� wit� capecitabine replacing 5-fluoroura-
cil� as according to t�e results of von Delius et al 
[��]. Doxorubicin was used at �.5 μg/mL� cisplatin 
at �.�5 μg/mL� capecitabine at �� μg/mL and inter-
feron α-�b at � μg/mL� corresponding to t�e concen-
trations used in t�e preclinical models t�at were later 
on followed by clinical trials [��]. N-Acetyl-L-Cysteine 
�NAC� was obtained from Organika �Buc�arest� Ro-
mania� and used a final concentration of �5 μg/ml� 
in order to fully assess t�e role of increased oxidative 
stress in t�e arm wit� metformin plus PIAF combina-
tion c�emot�erapy.
Cell culture. Cancer stem-like cells isolated 
as previusly described [��] �CSC cell line�� were cul-
tured along wit� normal liver stem cells �LIV cell line� 
and t�e non-stem tumor cell line HepG� �bot� kindly 
provided by t�e Assistant Professor Sergiu Susman� 
�D� P�D at Department of Histology� Iuliu Hatieganu 
University of �edicine and P�armacy from Cluj Na-
poca� Romania� and maintained in Ham’s F-�� and 
Dulbecco’s �odified Essential �edium at �:� ratio� 
supplemented wit� ��% fetal calf serum �FCS�� 
��� U/mL penicillin and ��� μg/mL streptomycin �all 
from Sigma Aldric�� St Louis� �O� USA� in a ��°C �u-
midified incubator wit� a mixture of 95% air and 5% 
carbon dioxide. All experiments were performed 
on exponentially growing cells� wit� a doubling time of 
ap proximately �� to �6 �. T�ese cells were previusly 
reported to express t�e stem cell specific markers 
albumin� α�-antitrypsin� α-fetoprotein� cytokera-
tin-�8� telomerase� CD9� and CD��� [��� ��].
Proliferation assay. Cell survival was assessed 
using t�e �TT assay. For �-���5-dimet�ylt�iazol-
�-yl�-��5-dip�enyltetrazolium bromide ��TT� as-
says� cancer cells in monolayer culture were cul-
tivated at subconfluence in D�E�:F-�� media 
supplemented wit� �5% FCS� ��� U/mL penicillin 
and ��� μg/mL streptomycin complete media before 
being was�ed twice wit� p�osp�ate buffer solution 
�PBS�. Cells were t�en incubated wit� trypsin-EDTA� 
resuspended in culture medium wit� FCS� counted and 
plated in ��� μL media at �5 x ��� cells/well in 96-well 
microtiter plates. After �� �� cells were was�ed and 
treated wit� eit�er metformin or N-Acetyl-L-Cysteine� 
before drugs being added. T�e control arms were 
compared wit� t�e corresponding conventional cyto-
statics at identical concentrations. Absorbance of t�e 
�TT was measured at �9� nm using a BioTek Synergy 
� fluorescence microplate reader �Winooski� VT� USA�.
Lipid peroxidation assay. For bot� t�e determi-
nation of lipid peroxidation and reduced glutat�ion� 
cells were seeded in �5 ml flasks at a density of � mil-
ions cells/flask. At �� and �8 � after treatments� cells 
were detac�ed wit� trypsin and centrifugated 5 min� 
�5�� rpm� at 9°C. T�e supernatant was removed and 
t�e pellet was suspended in � ml lysis solution. T�en 
eac� probe was sonicated to break t�e cellular mem-
branes. Peroxidase activity was determined by using 
t�e indirect met�od t�at measures t�e rate f disappea-
rance of NADPH� adapted to laboratory conditions. T�e 
reaction mixture consists of � m� GSH� �.�� U/ml glu-
tat�ione reducatse and �.�5 m� NADPH in 5� m� pBS 
at a pH of �. Appropiate volumes of samples were 
added for a final final reaction mixture incubated 
at ��°C for 5 min. T�e assay was initially performed 
wit� �� m� t-butyl �ydroperoxide solution� before 
a decrease in absorbance at ��� nm for anot�er � min. 
Lipid peroxidation activity was expressed as nmols 
NAPDH consumed/min/mg lipids and were calculated 
using 6.� x ���6 molar absorbtivity for NAPDH� as ac-
cording to Korde et al. [�5].
Reduced glutathione assay. Reduced GSH is an in-
tracellular antioxidant and is known to maintain cellular 
redox balance. We t�erefore measured intracellular 
GSH levels. Cell lysates were prepared as described 
above and analyzed for GSH levels t�roug� a fluori-
metric met�od due to its property to make a fluorescent 
reaction wit� o-p�talalde�yde. Cells are mixed wit� acid 
tric�loracetic �TCA� ��% and after �� min centrifuged. T�e 
supernatant was separated and �.� ml p�osp�ate buffer 
wit� pH 8 and � ml of o-parafolmalde�yde were added. 
After �5 min t�e intensity of emission at ��� nm on an ex-
citation of �5� nm was measured.
Glutat�ione concentration was measured using 
a calibration curve realized wit� known concentrations 
of glutat�ione obtained in t�e same way. Concentration 
values are expressed in nmol/ml.
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Dicloro-Fluorescein diacetate viability assay. 
96 wells plates were prepared in t�e same way as de-
scribed in proliferation �TT assay� seeded wit� cells 
and incubated for seven days. For t�e viability test 
wit� fluorescein diacetate �FDA-an indicator of cell 
viability�� cell monolayers were was�ed twice wit� PBS 
supplemented wit� �g�+  and Ca �+ and stained for 
5 min wit� FDA in t�e dark� at ��°C at a final concentra-
tion of ��� �. T�e wells were was�ed twice wit� PBS 
supplemented wit� �g�+  and Ca �+ and fluorescence 
intensity �FI� and were measured at �88 nm using 
a BioTek Synergy � fluorescence microplate reader. All 
t�e experiments were performed in triplicate.
Apoptosis quantification by chip flow cytometry. 
T�e cells were treated as described above and cultured 
for anot�er �� �. After incubation� t�e cells were trypsin-
ized� collected� and stained wit� Anexinn V-Cy5 Apopto-
sis Detection Kit �BioVision� for �� min in t�e dark. Calcein 
A� was used as a viability marker� t�e cells were incu-
bated wit� � μ� Calcein A� for �� min at ��°C� was�ed 
and quantified by on-c�ip flow cytometry according 
to t�e manufacturer instructions �Agilent Tec�nologies�. 
T�e number of apoptotic cells was assessed wit� Agilent 
Lab-on-a-c�ip Bioanalyzer ���� �Agilent Tec�nologies�� 
as percent of apoptotic cells in live cells.
Autophagy assay. T�e autop�agy assay was 
carried out using fluorescence microscopy and �ig�-
content imaging and analysis using cells previously fixed 
in �.�% paraformalde�yde in PBS and permeabilized 
wit� �.�% Triton X-��� diluted in PBS. T�en� t�e cells 
were treated wit� ������ μ� c�loroquine for �6 �� 
before t�e LC�B rabbit polyclonal antibody was diluted 
in blocking buffer in order to prepare �.5 μg/ml working 
solution. �.�% formalde�yde in PBS was added and 
incubated for �5 min at room temperature before t�e 
fixative was removed and cells was�ed t�ree times. 
T�e next step was to add �.�% Triton X-��� in PBS and 
cells were incubated for �5 min at room temperature. 
T�e permeabilization buffer was removed� t�e primary 
antibody added to t�e cells and incubated for � � be-
fore being once again removed and cells was�ed t�ree 
times. Cells were t�en incubated wit� an anti-rabbit sec-
ondary antibody for �5 min� was�ed t�ree times once 
more and additional DNA counterstaining was carried 
out. Images were taken using a Zeiss Axiovert fluores-
cence microscope and autop�agosomes looked like 
vesicular structures located in t�e perinuclear region.
Data analysis. Statistical significance values were 
obtained by a one-way analysis of variance �ANOVA� 
wit� 95% confidence level using Grap�Pad Prism 
5 statistics program �La Jolla� CA� USA�. Data were 
analyzed using one-way ANOVA wit� t�e Bonferroni 
multiple comparison test �Kruskal-Wallis as nonpara-
metric�. Statistical significance was set at p < �.�5 and 
all experiments were performed in triplicate.
RESULTS
Cell proliferation assay. �etformin doesn’t seem 
to in�ibit �epatocellular carcinoma-derived cancer stem-
like cell proliferation bot� at �� � and after �8 � �Fig. �� 
a and �� b�. Nevert�eless� t�e results are better w�en 
metformin plus PIAF combination c�emot�erapy was 
used and statistically signifficant data were obained� 
as seen in Table � �at �� �� and Table � �at �8 ��. T�is 
is especially important because �epatocarcinoma stem-
like cells �ave proven to be resistant to conventional 
treatment wit� cisplatin/doxorubicin/capecitabine.
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Fig. 1. T�e �TT cell proliferation assay s�ows t�at t�e combina-
tion of metformin plus PIAF is t�e best combination c�emot�erapy 
option possible for �epatocellular carcinoma� bot� at �� � �� a� 
and �8 � �� b�. Data is statistically significant �95% confidence 
interval�� as seen in Table � �data at �� �� and Table � �data at �8 ��
Table 1. MTT assay at 24 h
Statistically significant groups 95% CI of difference
Control vs Metformin 0.4726 to 1.058
Control vs Metformin + PIAF 0.5284 to 1.114
Control vs NAC + Metformin + PIAF 0.3860 to 0.9714
Control vs NAC + Metformin + PIAF 0.4878 to 1.073
Metformin vs PIAF -1.293 to -0.6168
Metformin vs NAC -1.267 to -0.5906
Metformin vs NAC + PIAF -1.124 to -0.4476
PIAF vs Metformin + PIAF 0.6726 to 1.349
PIAF vs NAC + Metformin + PIAF 0.5302 to 1.206
PIAF vs NAC + Metformin + PIAF 0.6320 to 1.308
Metformin + PIAF vs NAC -1.322 to -0.6464
Metformin + PIAF vs NAC + PIAF -1.179 to -0.5034
NAC vs NAC + Metformin + PIAF 0.5040 to 1.180
NAC vs NAC + Metformin + PIAF 0.6058 to 1.282
NAC + Metformin + PIAF vs NAC + PIAF -1.037 to -0.3610
NAC + PIAF vs NAC + Metformin + PIAF 0.4628 to 1.139
Determination of lipid peroxidation. �etformin 
increases t�e values of lipid peroxidation� bot� w�en 
used alone or w�en combined wit� conventional c�e-
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mot�erapy drugs at �� and �8 �� as seen in Fig. �� a and 
�� b. T�e most increased values of oxidative stress cor-
respond to t�e lowest proliferation rates obtained wit� t�e 
treatment metformin plus PIAF c�emot�erapy.
Table 2. MTT assay at 48 h
Statistically significant groups 95% CI of difference
Control vs Metformin 0.3236 to 0.5920
Control vs Metformin + PIAF 0.3742 to 0.6426
Control vs NAC + Metformin + PIAF 0.3206 to 0.5890
Control vs NAC + PIAF -0.2736 to -0.005188
Control vs NAC + Metformin + PIAF 0.3686 to 0.6370
Metformin vs PIAF -0.6104 to -0.3060
Metformin vs NAC -0.6648 to -0.3604
Metformin vs NAC + PIAF -0.7494 to -0.4450
PIAF vs Metformin + PIAF 0.3566 to 0.6610
PIAF vs NAC + Metformin + PIAF 0.3030 to 0.6074
PIAF vs NAC + Metformin + PIAF 0.3510 to 0.6554
Metformin + PIAF vs NAC -0.7154 to -0.4110
Metformin + PIAF vs NAC + PIAF -0.8000 to -0.4956
NAC vs NAC + Metformin + PIAF 0.3574 to 0.6618
NAC vs NAC + Metformin + PIAF 0.4054 to 0.7098
NAC + Metformin + PIAF vs NAC + PIAF -0.7464 to -0.4420
NAC + PIAF vs NAC + Metformin + PIAF 0.4900 to 0.7944
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Fig. 2. Lipid peroxidation values at �� � �a� and �8 � �b�
Determination of reduced glutathione. T�e 
initial �ypot�esis t�at oxidative stress plays a key role 
in t�e action of cytostatic drugs plus metformin in liver 
cancer cell in�ibition is confirmed bot� by t�e data ob-
tained from t�e determination of lipid peroxidation and 
reduced glutat�ione. Suc�� oxidative stress is most 
increased w�en using t�is combination c�emot�erapy� 
t�at is also corresponding to t�e lowest proliferation 
rates at �� � �Fig. �� a� and �8 � �Fig. �� b�.
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Fig. 3. Determination of reduced glutat�ione at �� � �a� and �8 � �b�.
Dicloro-FDA assay. T�e FDA assay confirms our 
previous results� confirming increased oxidative stress 
in cells t�at were treated wit� metformin plus cytostatics� 
in comparison wit� cells treated eit�er wit� metformin 
or PIAF� as illustrated in Fig. �. Data are s�own in Table �.
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Fig. 4. Determination of increased oxidative stress using t�e 
FDA assay
Apoptosis assay. After t�e incubation and 
staining wit� Anexinn V-Cy5 Apoptosis Detection Kit 
ad using calcein A� as a viability marker� t�e Agilent 
Lab-on-a-c�ip Bioanalyzer ���� tec�nology allowed 
us to assess t�e percentage of cells in apoptosis 
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as furt�er seen in Fig. 5. All t�e determinations were 
carried out in triplicate� according to data provided 
in Table �.
Table 3. FDA assay
Statistically significant groups 95% CI of difference
Control vs PIAF -632.2 to -267.8
Control vs Metformin + PIAF -871.2 to -506.8
Metformin vs PIAF -545.6 to -181.2
Metformin vs Metformin + PIAF -784.6 to -420.2
PIAF vs Metformin + PIAF -421.2 to -56.77
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Fig. 5. Apoptosis assay compares in triplicate all t�e � arms 
of our experiment� proving an increased apoptosis via oxidative 
stress in cells treated wit� metformin plus temozolomide. T�e 
data presented by using Agilent Lab-on-a-c�ip Bioanalyzer 
���� is seen  in t�e image presented bellow
Table 4. Apoptosis assay
Statistically significant groups 95% CI of difference
Control vs Metformin + PIAF -41.52 to -33.35
Metformin vs Metformin + PIAF -41.62 to -33.45
PIAF vs Metformin + PIAF -40.02 to -31.85
Autophagy assay. Autop�agy is confirmed 
by Fig. 6 �a� b�� in comparison wit� t�e control — 
as seen in Fig. 6 �c� d�. In t�e case of metformin 
plus PIAF combination c�emot�erapy� vesicular-like 
structures are seen in t�e perinuclear region of t�e 
cells after incubation wit� t�e secondary anti-rabbit 
monoclonal antibody and counterstaining of t�e 
cell nucleus wit� DAPI �diamindino-�-p�enylindole 
dye�. T�us� our initial �ypot�esis ans previous data 
obtained are confirmed.
DISCUSSION
�ost cases of HCC are diagnosed in an advanced 
stage because of t�e relatively scarce symptoms. 
T�us� t�e oncologist must rely liver imaging in order 
to proper assess t�e exact number and size of liver le-
sions� t�e location relative to t�e surrounding vessels� 
t�e nature or origin of t�e tumor and most important� 
t�e presence of extra�epatic spread. To t�e present 
day� t�ere is no internationally-accepted consensus re-
garding t�e best strategy for t�e imaging of liver tumors 
and it depends mostly on t�e request of t�e clinician� 
t�e condition of t�e patient and t�e equipment avai-
lable in t�e �ospital. �ost centers use ultrasound �US�� 
computed tomograp�y �CT� and magentic resonance 
a
c
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d
Fig. 6. Autop�agy assay confirms t�e presence of perinuclear autop�agososmes after staining wit� t�e secondary antibody �a� 
and counterstaining wit� DAPI of t�e nucleus �b�. Controls are seen in figures c and d
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imaging ��RI�� but some ot�ers tec�niques are avail-
able. T�ese include positron emission tomograpgy 
�PET�� a CT during an arterial portograp�y �CTAP� 
or during arteriograp�y �CTHA� and even laparoscopy 
wit� intraoperative ultrasound [�6��8].
CT-based scanning is a more sensitive examina-
tion for t�e detection of focal liver lesions. If it’s still 
not clear enog�� �RI �as an in�erent �ig� soft tussue 
contrast because tissue-specific electromagnetic 
paramaters suc� as t�e T� and T� relaxation time ef-
fect dominate t�e signal. So� �RI uses t�e many types 
of sequences t�at investigate a different tissue for 
eac� differential diagnosis between �ealt�y and pat�o-
logical liver parenc�yma. By using different contrast 
mec�anisms� t�e �RI can provide bot� anatomical 
and functional information� t�e c�emical s�ift imag-
ing being an example w�ere information is provided 
wit� regard to t�e intracellular fat content of t�e liver 
parenc�yma or a focal liver lesion [�9� ��].
Staging of t�e malignant liver mass is aimed 
to stratify patients into groups wit� similar prognoses� 
in order to �elp c�oose t�e best treatment� aid in pa-
tient counseling� allow comparisons of t�e outcome 
of different t�erapy protocols and last but certainly not 
least facilitate a good selection or randomization for 
reserac� protocols. In t�e cse of HCC� t�e most widely 
used in Europe and t�e US is t�e Barcelona Clinic Liver 
Cancer �BCLC� system� proposed in �999 due to its 
efficacy in bot� predicting prognosis and as a guide 
to select t�e most appropiate t�erapy [��]. Even 
if t�e BCLC staging was proven to be an efficient tool 
in prognostics� t�e treatment algoritm is mostly based 
on t�e Spanis� experience and is overly conserva-
tive wit� respect to t�e use of surgery. Patients wit� 
large tumors are excluded from surgical resection 
even if it �as been demonstrated a 5-year survival 
of �5 to �9% after resection� wit� radiofrequency ab-
lation and et�anol injection recommended for t�ose 
wit� multifocal disease t�at respect t�e �ilan criteria 
[��]. T�e AJCC/UICC 6t� edition TN� staging system 
is based on a study of t�e International Cooperative 
Study Group on Hepatocellular Carcinoma� a analysis 
of 59� cases from t�e US� Japan and France� w�o 
all underwent surgical resection [��� ��]. T�e major 
streng�t� is t�e use of centralized pat�ological review� 
focusing on tumor multifocality� size and presence 
of microvascular or major vascular c�aracteristics 
of prognostic significance. It also brings toget�er t�e 
data of liver fibrosis and cirr�osis based on t�e Is�ak 
�istological grading� but t�e most important limitation 
is t�at it was developed based only on resected tissue 
and it’s applicability to patients undergoing ot�er non-
sugical locoregional treatments is questionable [�5].
But still� even t�oug� we take into consideration 
t�e most permissive staging possible� most of t�e 
patients diagnosed wit� a HCC are not eligible for 
surgical resection. T�ese patients are considered 
to be incurable and in order to ac�ieve a good quality 
of life t�roug� increased toxicity for t�e cancer cells 
and decresed toxicity for t�e �ealt�y tissue� modern 
�epatology must develop a differet approac�� based 
on recently publis�ed data. T�is very concept in used 
in t�e current study. By experimenting on cancer cells 
previously proven to �ave stem-like c�aracteristics� 
our preliminary in vitro results aim to target t�e small 
but very aggressive subpopulation t�oug�t to be re-
sponsible for clinical relapse and patient deat�.
Encouraging results �ave emerged from recent 
data publis�ed on breast cancer and point towards 
metformin� an oral-antidiabetic used for decades in t�e 
treatment of type � diabetes mellitus� as an efﬁcient 
anticancer drug. �etformin �as been investigated 
by our team for t�e treatment of WHO grade III and 
IV malignant gliomas in t�e laboratory setting and t�e 
results were furt�er conﬁrmed by retrospective epide-
miological studies t�at reported a decrease in cancer 
risk and also a better response to c�emot�erapy 
of diabetic patients wit� breast cancer treated wit� 
metformin [�6� �].
Still� despite compelling evidence of a role 
of metformin as an anticancer drug� t�e mec�anisms 
by w�ic� metformin exerts its oncostatic actions are 
yet not fully understood. In t�e current researc� paper� 
we studied t�e effect of metformin plus PIAF combi-
nation c�emot�erapy on HCC-derived stem-like cells 
in order to furt�er investigate t�e basic mec�anisms 
by w�ic� t�is association of drugs exerts its action 
on t�e cancer cell. T�is study demonstrates for t�e 
first time t�at t�e association between metformin and 
conventional is linked to t�e generation of oxidative 
stress� en�ancing its anti-neoplastic action. Recent 
evidence s�ows t�at metformin decreases t�e reactive 
oxigen species �ROS� in �ealt�y cells because of its 
antioxidant and free radical scavenging abilities. Suc� 
is t�e case of normal rat pancreatic islets� w�ere 
metformin �as been proven to reduce t�e oxida-
tive stress induced by c�ronic exposure to �ig� 
free fatty acids and restore t�e antioxidant status 
in type � diabetic patients. Our results confirm t�is 
experiment and furt�ermore� even if metformin �as 
demonstrated powerful anti-oxidant properties in nor-
mal cells� in cancer stem-like ones isolated from a liver 
tumor it stimulates t�e production of oxidative stress 
bot� alone or in combination wit� c�emot�erapy. In-
creased values of oxidative stress are correlated wit� 
decreased proliferation rates� t�us contradicting t�e 
observation t�at oxidative stress contributes to drug 
resistance.
Cellular redox �omeostasis is t�us maintained 
by a fine balance between antioxidants and pro-
oxidants. Glutat�ione �GSH� is a critical intracellular 
antioxidant responsible for maintaining redox balance 
t�at can be oxidized to form a more complex structure 
�GSSG�� wit� t�e ratio GSH/GSSG being a excellent 
indicator of oxidative stress in t�e cells [��]. Decreased 
GSH levels will indicate t�e s�ift of redox equilibrium 
towards a pro-oxidant state. Our results s�ow t�at t�e 
association between metformin and temozolomide �as 
low values of reduced glutat�ione� w�ic� correlates 
wit� t�e increase production of lipid peroxids.
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It is well known t�at most of t�e liver pat�ology� may 
it be non-alco�olic fatty liver disease �NAFLD�� non-
alco�olic steato�epatitis �NASH� syndrome� cirr�osis 
and even �epatocellular carcinoma develop partially 
due to an underlying constellation of closely related 
risk factors known as metabolic syndrome or syn-
drome X [�8���]. Wit� a rapidly growing prevalence 
in t�e Western world� t�is syndrome is c�aracterized 
by obesity� insulin resistance� �yperinsulinemia� �y-
perglycaemia� dyslipidemia and �ypertension. As t�e 
first step in disease appearance and development 
is t�e accumulation of triglycerides in t�e �epatocyte 
as a result of perip�eric insulin resistance. In time� 
t�is will result in increased oxidative stress wit�in t�e 
liver cell due to excessive production of ROS by t�e 
mitoc�ondria and t�e cytoc�rome P-�5� system 
and afterwards� an increse in lipid peroxidation� 
pro-inflammatory cytokine and Fas ligand induction 
promotes t�e progression from steatosis to NASH� 
fibrosis and finally cirr�osis [����5]. W�en cirr�osis 
appears� t�e natural �istory of t�e liver parenc�yma 
most often evolves to eit�er �epatocellular carcinoma 
or c�olnagiocarcinoma. Our data is supported by t�is 
circuit of pat�ological c�anges of t�e �epatic tissue 
and it is only natural t�at a drugs known for its action 
against various features and risk factors of metabolic 
syndrome via oxidative stress to en�ance t�e effect 
of various cytostsic drugs and increase toxicity in t�e 
malignant cell w�ile decreasing t�e same toxic effects 
in t�e �ealt�y tissue.
CONCLUSIONS
Hepatocellular carcinomas are �eterogeneous 
tumors wit� an inpredicable and most often let�al 
clinical course. As t�e molecular approac�� previusly 
t�oug�t to c�ange t�e management of a patient di-
agnosed wit� t�is dreadfull disease� �as proven most 
often less effective t�an t�e classic approac�� our 
researc� team turned to a drug used in t�e clinic for 
decades and combines t�is oral antidiabetic wit� best 
supportive care for advanced stage HCC. Our resuls 
confirm previusly publis�ed papers t�at report t�e 
sensitizing effect of metformin to tamoxifen t�erapy for 
women wit� HER�/neu + breast cancer. Still� furt�er 
data on animal models and retrospective analysis are 
needed before we make a step forward in t�e field� 
to p�ase I clinical trials� and start prescribing metfor-
min along wit� PIAF combination c�emot�erapy for 
�epatocellular carcinoma tteatment.
ACKNOWLEDGEMENTS AND FUNDING
T�is researc� �as never been publis�ed before and 
was financially supported by a researc� grant of t�e 
Iuliu Hatieganu University of �edicine and P�armacy� 
granted to Bobe Petrus�ev — �D. All t�e experiments 
were carried out bot� at t�e Department of Cancer 
Immunology� Ion C�iricuta Compre�ensive Cancer 
Center in Cluj Napoca and at t�e G.I. Core Center 
at Jo�ns Hopkins University� under t�e supervision 
of Ciprian Tomuleasa� �D �Postdoctoral Researc�er 
at T�e Jo�ns Hopkins University in Baltimore� �D� 
USA� and Professor Victor Cristea� �D� P�D �Head 
of Department and Attending p�ysician in Clinical 
Gastroenterology and Hepatology at t�e Octavian 
Fodor Regional Institute of Gastroenterology and 
Hepato logy� Cluj Napoca� Romania�.
CONFLICTS OF INTEREST
None declared.
REFERENCES
1. Papavramidou N, Fee E, Christopoulou-Aletra H. 
Jaundice in the Hippocratic corpus. J Gastrointest Surg 2007; 
11: 1728–31.
2. Lykouras E, Poulakou-Rebelakou E, Ploumpi-
dis DN. Searching the seat of the soul in Ancient Greek and 
Byzantine medical literature. Acta Cardiol 2010; 65: 619–26.
3. Reuben A. The way to a man’s heart is through his liver. 
Hepatology 2003; 37: 1500–2.
4. Hammerschmidt DE. Prometheus. J Lab Clin Med 
2000; 135: 498.
5. Altekruse SF, McGlynn KA, Reichman ME. Hepato-
cellular carcinoma incidence, mortality, and survival trends 
in the United States from 1975 to 2005. J Clin Oncol 2009; 
27: 1485–91.
6. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 
2011; 365: 1118–27.
7. Ryder SD. British Society of Gastroenterology. Guide-
lines for the diagnosis and treatment of hepatocellular carci-
noma (HCC) in adults. Gut 2003; 52: iii1–8.
8. Gonzalez-Angulo AM, Meric-Bernstam F. Metfor-
min: a therapeutic opportunity in breast cancer. Clin Cancer 
Res 2010; 16: 1695–700.
9. Soritau O, Tomuleasa C, Aldea M, et al. Metformin 
plus temozolomide-based chemotherapy as adjuvant treat-
ment for WHO grade III and IV malignant gliomas. J BUON 
2011; 16: 282–9.
10. Jiralerspong S, Palla SL, Giordano SH, et al. Met-
formin and pathologic complete responses to neoadjuvant 
chemotherapy in diabetic patients with breast cancer. J Clin 
Oncol 2009; 27: 3297–302.
11. von Delius S, Lersch C, Mayr M, et al. Capecitabine 
for treatment of advanced hepatocellular carcinom ma. Hepa-
togastroenterology 2007; 54: 2310–4.
12. Yeo W, Mok TS, Zee B, et al. A randomized phase III 
study of doxorubicin versus cisplatin/interferon alpha-2b/
doxorubicin/fluorouracil (PIAF) combination chemotherapy 
for unresectable hepatocellular carcinoma. J Natl Cancer Inst 
2005; 97: 1532–8.
13. Tomuleasa C, Soritau O, Rus-Ciuca D, et al. Isolation 
and characterization of hepatic cancer cells with stem-like 
properties from hepatocellular carcinoma. J Gastrointestin 
Liver Dis 2010; 19: 61–7.
14. Tomuleasa C, Soritau O, Fischer-Fodor E, et al. 
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/ 
capecitabine combination chemotherapy for unresectable 
hepatocellular carcinoma. Hematol Oncol Stem Cell Ther 
2011; 4: 60–6.
15. Korde SD, Basak A, Chaudhary M, et al. Enhanced 
nitrosative and oxidative stress with decreased total antioxidant 
capacity in patients with oral precancer and oral squamous cell 
carcinoma. Oncology 2011; 80: 382–9.
16. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Di-
agnosis and treatment of hepatocellular carcinoma. Gastro-
enterology 2008; 134: 1752–63.
�� Experimental Oncology ��� ������ ���� ��arc��
17. Forner A, Reig ME, de Lope CR, Bruix J. Current 
strategy for staging and treatment: the BCLC update and future 
prospects. Semin Liver Dis 2010; 30: 61–74.
18. Silva MA, Hegab B, Hyde C, et al. Needle track seeding 
following biopsy of liver lesions in the diagnosis of hepatocel-
lular cancer: a systematic review and meta-analysis. Gut 2008; 
57: 1592–6.
19. Suh YJ, Kim MJ, Choi JY, et al. Differentiation 
of hepatic hyperintense lesions seen on gadoxetic acid-
enhanced hepatobiliary phase MRI. Am J Roentgenol 2011; 
197: W44–52.
20.  El-Serag HB. Surveillance for hepatocellular carci-
noma: in whom and how? Therap Adv Gastroenterol 2011; 
4: 5–10.
21. Llovet JM, Brъ C, Bruix J. Prognosis of hepatocellular 
carcinoma: the BCLC staging classification. Semin Liver Dis 
1999; 19: 329–38.
22. Forner A, Reig ME, de Lope CR, Bruix J. Current 
strategy for staging and treatment: the BCLC update and future 
prospects. Semin Liver Dis 2010; 30: 61–74.
23. Varotti G, Ramacciato G, Ercolani G, et al. Compari-
son between the fifth and sixth editions of the AJCC/UICC 
TNM staging systems for hepatocellular carcinoma: multicen-
tric study on 393 cirrhotic resected patients. Eur J Surg Oncol 
2005; 31: 760–7.
24. Zhou L, Rui JA, Wang SB, et al. LCSGJ-T classification, 
6th or 5th edition TNM staging did not independently predict the 
long-term prognosis of HBV-related hepatocellular carcinoma 
after radical hepatectomy. J Surg Res 2010; 159: 538–44.
25. Zhou L, Rui JA, Ye DX, et al. Edmondson-Steiner 
grading increases the predictive efficiency of TNM staging for 
long-term survival of patients with hepatocellular carcinoma 
after curative resection. World J Surg 2008; 32: 1748–56.
26. Dowling RJ, Goodwin PJ, Stambolic V. Understan-
ding the benefit of metformin use in cancer treatment. BMC 
Med 2011; 9: 33.
27. Hadad S, Iwamoto T, Jordan L, et al. Evidence for 
biological effects of metformin in operable breast cancer: a pre-
operative, window-of-opportunity, randomized trial. Breast 
Cancer Res Treat 2011; 128: 783–94.
28. Burhans WC, Heintz NH. The cell cycle is a redox 
cycle: linking phase-specific targets to cell fate. Free Radic 
Biol Med 2009; 47: 1282–93.
29. Donohoe CL, Pidgeon GP, Lysaght J, Reynolds 
JV. Obesity and gastrointestinal cancer. Br J Surg 2010; 
97: 628–42.
30. Lackner C. Hepatocellular ballooning in nonalcoholic 
steatohepatitis: the pathologist’s perspective. Expert Rev Gas-
troenterol Hepatol 2011; 5: 223–31.
31. Lebovics E, Rubin J. Non-alcoholic fatty liver disease 
(NAFLD): why you should care, when you should worry, what 
you should do. Diabetes Metab Res Rev 2011; 27: 419–24.
32. Liu Q, Bengmark S, Qu S. The role of hepatic fat ac-
cumulation in pathogenesis of non-alcoholic fatty liver disease 
(NAFLD). Lipids Health Dis 2010; 9: 42.
33. Mirza MS. Obesity, visceral fat, and NAFLD: query-
ing the role of adipokines in the progression of nonalcoholic 
fatty liver disease. ISRN Gastroenterol 2011; 2011: 592–404.
34. Kashyap SR, Diab DL, Baker AR, et al. Triglyceride 
levels and not adipokine concentrations are closely related 
to severity of nonalcoholic fatty liver disease in an obesity 
surgery cohort. Obesity (Silver Spring) 2009; 17: 1696–701.
35. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic 
syndrome increases the risk of primary liver cancer in the 
United States: a study in the SEER-Medicare database. Hepa-
tology 2011; 54: 463–71.
Copyright © Experimental Oncology, 2012
